In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:

• TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan
• TROP2 ADCS for patients with EGFR-mutated NSCLC
• TIGIT-targeting agents: domvanalimab, rilvegostomig

Presenters:

Benjamin Levy, MD, FASCO
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)
Washington, DC

Alex Spira, MD, PhD, FASCO
Director Clinical Research
Virginia Cancer Specialists
CEO NEXT Oncology Virginia
Fairfax, Virginia

Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.

Link to full program:
https://bit.ly/4qZLR6B

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:

• Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection
• The recently approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC (RAMP 201)
• Promising future directions for patients with LGSOC based on ongoing studies such as RAMP 301 and CHAMELEON
  

Presenters:
Rachel Grisham, MD
Section Head of Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Director Gynecologic Medical Oncology, MSKCC Westchester
New York, New York

Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB/Gyn
ASCO BOD
Oklahoma City, Oklahoma

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:

• Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer
• Results of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant disease
• How R-DXd may be incorporated into the treatment paradigm
• Other investigational CDH6-targeting ADCs: CUSP06, SIM0505

Presenters:

Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB/Gyn
ASCO BOD
Oklahoma City, Oklahoma

Isabelle Ray-Coquard, MD, PhD
President of the Gineco Group
Centre Leon Bérard
Reshape Lab Inserm u1290
Université Claude Bernard Lyon Est
Lyon, France

Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Link to full program:
https://bit.ly/43PXoeP

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.